Contact Us

Empowering Advanced Therapies

Innoforce is a partnership-focused biopharmaceutical company established to enable and accelerate the innovation of breakthrough advanced therapies and biologics. Innoforce offers end-to-end contract development and manufacturing service (CDMO), including GMP manufacturing of RNA, plasmid DNA, viral vector and cell products. In addition, through a joint venture with a leading international supplier of life sciences products and services, the company provides CDMO services for antibody and protein drugs. Innoforce’s enabling capabilities for developing cell, gene, and advanced biological therapies can support partners to rapidly and efficiently bring cutting-edge treatments that impact patients’ lives worldwide.

We are self-driven entrepreneurs with a great passion for propelling global biopharmaceutical development. Our leadership team is composed of seasoned scientific leaders and organizational executives. We have a proven track record in international business, from discovery and development to commercialization. Our team also brings world-class expertise in biopharmaceutical CMC and the manufacturing of high-quality medicines. Find out more about the leadership team here.

Corporate Milestones

Innoforce was founded in 2018 by a group led by Dr. Guoliang Yu, a renowned scientist & biotechnology entrepreneur, and Dr. Yuling Li, a seasoned biopharmaceutical executive. The company has raised over $175M in capital to-date.

keywords:mRNA CDMO mRNA CDMO